PRA, MERCK KGAA WILL ASSIST BIOMIRA WITH LUNG CANCER TRIAL

Biomira announced that PRA International will assist Biomira and Merck KGaA of Darmstadt, Germany, with the planned Phase III trial of BLP25 Liposome Vaccine for the treatment of non-small cell lung cancer.

The study is expected to commence toward the end of the year. The trial design is currently being discussed with the FDA.